Holen Sie sich die Stockscreener-App
303.01
0.23%
0.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$303.07
Offen:
$306.51
24-Stunden-Volumen:
280.85K
Relative Volume:
0.16
Marktkapitalisierung:
$59.00B
Einnahmen:
$328.68B
Nettoeinkommen (Verlust:
$2.55B
KGV:
23.25
EPS:
13.0349
Netto-Cashflow:
$1.56B
1W Leistung:
+2.43%
1M Leistung:
+11.97%
6M Leistung:
-13.82%
1J Leistung:
+3.68%
1-Tages-Spanne:
$301.85
$308.81
1-Wochen-Bereich:
$298.73
$313.90
52-Wochen-Spanne:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
303.26 | 59.14B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
823.68 | 97.35B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
225.38 | 52.87B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
84.87 | 9.82B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.49 | 1.35B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
ABC5953643 Bond Risk Profile - TradingView
Cencora stock trades steadily as pharmaceuticals distributor highlights rising revenue and earnings - Ad-hoc-news.de
Cencora, Inc. Stock 12‑Month Price Target Raised to $354.58, Implies 17% Upside - TradingView
Cencora earnings preview: What to expect - MSN
ETFs Investing in Cencora, Inc. Stocks - TradingView
Cencora stock trades near record levels as earnings and guidance underpin healthcare distribution gr - Ad-hoc-news.de
Cencora Inc. stock underperforms Monday when compared to competitors - MarketWatch
Cencora stock holds firm as revenue and profit trends stay in focus - Ad-hoc-news.de
US3073EBC8 Bond Risk Profile - TradingView
Cencora stock trades near record levels as specialty distribution growth supports earnings - Ad-hoc-news.de
Steve Collis: Pharmaceutical Distribution Leader and Former Chairman, President, and CEO of Cencora - BBN Times
Cencora stock holds after fiscal 2026 growth update - ad-hoc-news.de
Cencora stock trades steadily as recent earnings highlight solid revenue growth - ad-hoc-news.de
XS3071246378 Bond Risk Profile - TradingView
XS3071246378 Bond Coupon Profile — Rate & Payments - TradingView
ABC6310083 Bond Coupon Profile — Rate & Payments - TradingView
XS3071246378 Bond Profile — Key Metrics - TradingView
Cencora stock trades steadily as specialty distribution growth supports earnings - Ad-hoc-news.de
Fund Update: 235,570 CENCORA (COR) shares added to FORT WASHINGTON INVESTMENT ADVISORS INC |OH| portfolio - Quiver Quantitative
Cencora Earnings Preview: What to Expect - Yahoo Finance
A1ZW87 Bond Coupon Profile — Rate & Payments - TradingView
Lobbying Update: $60,000 of CENCORA INC. lobbying was just disclosed - Quiver Quantitative
ABC6310086 Bond Profile — Key Metrics - TradingView
Is Cencora Inc (COR) Overvalued After 3.9% Rally? GF Value Says - GuruFocus
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora stock reflects steady healthcare distribution role as investors track U.S. drug spending tre - ad-hoc-news.de
Cencora Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
ABC5953320 Bond Risk Profile - TradingView
ABC4571978 Bond Coupon Profile — Rate & Payments - TradingView
How Cencora’s Revenue Miss Amid Growth Will Impact Cencora (COR) Investors - simplywall.st
ABC5953320 Bond Profile — Key Metrics - TradingView
ABC6310084 Bond Coupon Profile — Rate & Payments - TradingView
ABGB Bond Profile — Key Metrics - TradingView
ABC6310085 Bond Coupon Profile — Rate & Payments - TradingView
Cencora stock reflects steady growth as healthcare distribution evolves - Ad Hoc News
Cencora Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Cencora (COR) Following Soft Earnings Is The Stock Starting To Look Undervalued - simplywall.st
ABC4987224 Bond Risk Profile - TradingView
Cencora : World Courier Expands Cold Chain Capabilities | Cencora - marketscreener.com
ABC4987224 Bond Profile — Key Metrics - TradingView
Cencora stock reflects steady growth in pharmaceutical distribution and services - Ad-hoc-news.de
Cencora stock reflects steady healthcare distribution role in a complex market - Ad-hoc-news.de
Cencora (COR) Stock Still Looks Undervalued On Cash Flow And Earnings - simplywall.st
Deals tracker: IKS Health acquires TruBridge in $557M deal - Modern Healthcare
Cencora stock trades steadily as healthcare distribution scale supports long-term growth - ad-hoc-news.de
Cencora Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Pricing Headwinds and Industry Trends Cut Into Cencora's 2026 Sales, but Fundamentals Remain Strong - Morningstar
Centene Corp navigates Medicaid shifts. Investors track managed care margins - Ad-hoc-news.de
Cencora Inc. focuses on pharmaceutical distribution scale as investors eye healthcare demand - ad-hoc-news.de
AQR Managed Futures Strategy Fund's Cencora Inc(COR) Holding History - GuruFocus
Form 4 Cencora Inc For: 7 July By Investing.com - Investing.com Nigeria
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):